PT1891961E - Uso de 5'-metiltioadenosina (mta) na prevenção e/ou no tratamento de doenças auto-imunes e/ou rejeição de transplante - Google Patents

Uso de 5'-metiltioadenosina (mta) na prevenção e/ou no tratamento de doenças auto-imunes e/ou rejeição de transplante Download PDF

Info

Publication number
PT1891961E
PT1891961E PT05728461T PT05728461T PT1891961E PT 1891961 E PT1891961 E PT 1891961E PT 05728461 T PT05728461 T PT 05728461T PT 05728461 T PT05728461 T PT 05728461T PT 1891961 E PT1891961 E PT 1891961E
Authority
PT
Portugal
Prior art keywords
prevention
treatment
methylthioadenosine
mta
autoimmune diseases
Prior art date
Application number
PT05728461T
Other languages
English (en)
Inventor
Pablo Villoslada Diaz
Matias Avila Zaragoza
Beatriz Moreno Bruna
Fernando Corrales Izquierdo
Carmen Berasain Lasarte
Elena Ruiz Garcia-Trevijano
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of PT1891961E publication Critical patent/PT1891961E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PT05728461T 2005-03-17 2005-03-17 Uso de 5'-metiltioadenosina (mta) na prevenção e/ou no tratamento de doenças auto-imunes e/ou rejeição de transplante PT1891961E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2005/000139 WO2006097547A1 (es) 2005-03-17 2005-03-17 Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes

Publications (1)

Publication Number Publication Date
PT1891961E true PT1891961E (pt) 2009-12-17

Family

ID=36991307

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05728461T PT1891961E (pt) 2005-03-17 2005-03-17 Uso de 5'-metiltioadenosina (mta) na prevenção e/ou no tratamento de doenças auto-imunes e/ou rejeição de transplante

Country Status (19)

Country Link
US (1) US7820637B2 (pt)
EP (1) EP1891961B1 (pt)
JP (1) JP2008533107A (pt)
CN (1) CN101141970A (pt)
AT (1) ATE442854T1 (pt)
AU (1) AU2005329287B2 (pt)
BR (1) BRPI0520129A2 (pt)
CA (1) CA2601557A1 (pt)
CY (1) CY1109539T1 (pt)
DE (1) DE602005016729D1 (pt)
DK (1) DK1891961T3 (pt)
ES (1) ES2334924T3 (pt)
HR (1) HRP20090646T1 (pt)
MX (1) MX2007011327A (pt)
PL (1) PL1891961T3 (pt)
PT (1) PT1891961E (pt)
RS (1) RS51122B (pt)
SI (1) SI1891961T1 (pt)
WO (1) WO2006097547A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
CN102573854A (zh) * 2009-06-11 2012-07-11 普罗耶克托生物医学Cima有限公司 5’-甲硫腺苷的神经保护特性
WO2011054990A2 (es) * 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal
JP5801572B2 (ja) * 2011-03-03 2015-10-28 シーシーアイ株式会社 ＰＰＡＲγ活性化剤
CN105153042B (zh) * 2015-07-17 2017-11-24 四川大学 一种化合物及其在制备治疗可卡因成瘾的药物中的用途
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
WO2020206299A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
CN114515294A (zh) 2022-02-25 2022-05-20 浙江中医药大学 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1193529B (it) * 1980-04-22 1988-07-08 Bioresearch Srl Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
ATE271063T1 (de) * 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
CA2306811A1 (en) * 1997-10-14 1999-04-22 Yoshiyuki Aoki Piperazine compounds and medicinal use thereof
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
JP2001072660A (ja) * 1999-09-08 2001-03-21 Welfide Corp ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
AU2001241067A1 (en) * 2000-03-09 2001-09-17 Ono Pharmaceutical Co. Ltd. Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes

Also Published As

Publication number Publication date
RS51122B (sr) 2010-10-31
SI1891961T1 (sl) 2010-01-29
DK1891961T3 (da) 2009-12-21
MX2007011327A (es) 2008-01-28
US7820637B2 (en) 2010-10-26
AU2005329287B2 (en) 2011-01-27
EP1891961A1 (en) 2008-02-27
EP1891961B1 (en) 2009-09-16
DE602005016729D1 (de) 2009-10-29
ES2334924T3 (es) 2010-03-17
HRP20090646T1 (hr) 2010-01-31
AU2005329287A1 (en) 2006-09-21
ATE442854T1 (de) 2009-10-15
PL1891961T3 (pl) 2010-02-26
CY1109539T1 (el) 2014-08-13
US20090042831A1 (en) 2009-02-12
JP2008533107A (ja) 2008-08-21
CA2601557A1 (en) 2006-09-21
BRPI0520129A2 (pt) 2009-04-28
CN101141970A (zh) 2008-03-12
WO2006097547A1 (es) 2006-09-21

Similar Documents

Publication Publication Date Title
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
PL1891961T3 (pl) Zastosowanie 5'-metylotioadenozyny (mta) w zapobieganiu i/lub leczeniu chorób autoimmunologicznych i/lub odrzucania przeszczepu
MY144318A (en) Methods of treating hiv infection.
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
HK1082435A1 (en) Compositions and methods for coating medical implants
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2006034001A3 (en) Methods of treating hiv infection
EP1676512A3 (en) Skin treatment articles and methods
BE2013C064I2 (pt)
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
IL174636A0 (en) Compositions containing anti-scarring agents and medical implants incorporating the same
IL171653A (en) History of aminocyclohexyl ether and pharmacy preparations containing them
HK1111083A1 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
EP1753777A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING HIV INFECTION WITH TRIM5a
WO2007059226A3 (en) Photoactivatable antimicrobial agents
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2006079121A3 (en) Methods of treating disease with glycosylated interferon
GB2401044B (en) A composition for use in the treatment or prophylaxis of a skin condition in a subject
MY176850A (en) Aminocyclohexyl ether compounds and uses thereof
TW200509940A (en) Pharmaceutical composition